TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12487013

Group type: EXPERIMENTAL
Intervention: Videotape intervention for sexual counseling after MI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual written and verbal instructions while hospitalized
Number of subjects: 0
Study: 9807202

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 349

Group type: COMPARATOR
Intervention: CMF regimen
Number of subjects: 349
Study: 7510510

Group type: EXPERIMENTAL
Intervention: Extradural analgesia to T4-S5 in addition to general anaesthetic
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standardized general anaesthetic
Number of subjects: 16
Study: 2660519

Group type: EXPERIMENTAL
Intervention: Muroctasin 100 micrograms
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Muroctasin 50 micrograms
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Muroctasin (both doses)
Number of subjects: 32
Study: 29077862

Group type: EXPERIMENTAL
Intervention: ASP requiring re-authorization of restricted antibiotics on day 3
Number of subjects: 166
Study: 26747333

Group type: EXPERIMENTAL
Intervention: 60,000 IU of vitamin D3
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 24,000 IU of vitamin D3 plus 300 μg of calcifediol
Number of subjects: 200

Group type: COMPARATOR
Intervention: 24,000 IU of vitamin D3 (control group)
Number of subjects: 200
Study: 26415294

Group type: EXPERIMENTAL
Intervention: Kruarone 0.6 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Esmerone
Number of subjects: 80
Study: 24146327

Group type: EXPERIMENTAL
Intervention: Active brown adipose tissue (BAT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Negative control (no detectable BAT)
Number of subjects: 62
Study: 20920765

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg) + Budesonide (200 μg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Budesonide (200 μg)
Number of subjects: 50
Study: 18713092

Group type: EXPERIMENTAL
Intervention: TASB (thoracic anti-supine band)
Number of subjects: 20

Group type: COMPARATOR
Intervention: nCPAP (nasal CPAP)
Number of subjects: 20
Study: 17015817

Group type: EXPERIMENTAL
Intervention: Ramelteon (16, 80, or 160 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Triazolam (0.25, 0.5, or 0.75 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 12821462

Group type: EXPERIMENTAL
Intervention: Gemifloxacin administered alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gemifloxacin administered simultaneously with calcium carbonate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Gemifloxacin administered 2 h before calcium carbonate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Gemifloxacin administered 2 h after calcium carbonate
Number of subjects: 16
Study: 10804490

Group type: EXPERIMENTAL
Intervention: Suture closure of the subcutaneous tissue
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Placement of a subcutaneous closed suction drain
Number of subjects: 76

Group type: COMPARATOR
Intervention: Neither suture closure nor drainage
Number of subjects: 76
Study: 8692149

Group type: EXPERIMENTAL
Intervention: Continuous hyperthermic peritoneal perfusion (CHPP)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (no CHPP)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Patients without intraperitoneal free cancer cells treated with CHPP
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (patients without free cancer cells)
Number of subjects: 234
Study: 1458623

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Neither procedure
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 201
Study: 6517150

Group type: EXPERIMENTAL
Intervention: Endolymphatic sac-mastoid shunt surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo operation (mastoidectomy)
Number of subjects: 30
Study: 31518454

Group type: EXPERIMENTAL
Intervention: Triangular neck implant (test)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Round neck implant (control)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both implants (triangular and round neck)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Triangular neck implant
Number of subjects: 32
Study: 30072156

Group type: EXPERIMENTAL
Intervention: CR + sedentary prompts from an activPAL3‐VT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care CR
Number of subjects: 40
Study: 27189287

Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 24587355

Group type: EXPERIMENTAL
Intervention: 20 mg AMP at encoding and placebo at retrieval (condition AP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Placebo at encoding and AMP at retrieval (condition PA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AMP at encoding and retrieval (condition AA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo at encoding and retrieval (condition PP)
Number of subjects: 80
Study: 22341993

Group type: EXPERIMENTAL
Intervention: 5 k Bq/kg radium-223
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 25 k Bq/kg radium-223
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 50 k Bq/kg radium-223
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 100 k Bq/kg radium-223
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All dose groups
Number of subjects: 100
Study: 20235191

Group type: EXPERIMENTAL
Intervention: Tilt whole-body vibration (WBV) intervention, 30-minute session of instruction plus 3 sessions of WBV per week for 12 weeks, 6 repetitions of 45-60 seconds at 12.5 Hz
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Tilt whole-body vibration (WBV) intervention
Number of subjects: 41
Study: 17563841

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 15756512

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12546313

Group type: EXPERIMENTAL
Intervention: Intravenous meperidine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 84
Study: 9534917

Group type: EXPERIMENTAL
Intervention: Azelastine
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 7885501

Group type: EXPERIMENTAL
Intervention: Surgery for colon cancer
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Dukes staging system
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Tumour size and shape, central lymph node involvement
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Follow-up after surgery
Number of subjects: 141
Study: 2234715

Group type: EXPERIMENTAL
Intervention: Elective delivery 48 hours after administration of betamethasone (aggressive-management group)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Delivery later as indicated by maternal or fetal condition (expectant-management group)
Number of subjects: 58
Study: 736293

Group type: EXPERIMENTAL
Intervention: Atropine, 0.4 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate, 0.2 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Saline solution, 1 ml
Number of subjects: 300

Group type: COMPARATOR
Intervention: No anticholinergic drug
Number of subjects: 300
Study: 29218381

Group type: EXPERIMENTAL
Intervention: Two-step screening program using FRAX and DXA scan
Number of subjects: 34229

Group type: EXPERIMENTAL
Intervention: DXA scanning in moderate- to high-risk women
Number of subjects: 34229

Group type: COMPARATOR
Intervention: Control group (office-based case-finding strategy)
Number of subjects: 34229
Study: 27752750

Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Functional MRI (fMRI)
Number of subjects: 150
Study: 26067552

Group type: EXPERIMENTAL
Intervention: Home-based exercise program for 6 months
Number of subjects: 59

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 59
Study: 24067488

Group type: EXPERIMENTAL
Intervention: Nurse-led algorithm-based treatment
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Gastroenterologist-led algorithm-based treatment
Number of subjects: 218
Study: 21424588

Group type: EXPERIMENTAL
Intervention: Nasal cannula (5 L/min)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Face mask (5 L/min)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 90
Study: 18344727

Group type: EXPERIMENTAL
Intervention: Venlafaxine monotherapy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Lithium carbonate monotherapy
Number of subjects: 83
Study: 15607840

Group type: EXPERIMENTAL
Intervention: Illicit use of prescription pain medication from peers
Number of subjects: 9161

Group type: EXPERIMENTAL
Intervention: Illicit use of prescription pain medication from family members
Number of subjects: 9161

Group type: EXPERIMENTAL
Intervention: Previous prescription of pain medication
Number of subjects: 9161

Group type: EXPERIMENTAL
Intervention: Living in a house or apartment
Number of subjects: 9161

Group type: EXPERIMENTAL
Intervention: Lower grade point averages
Number of subjects: 9161
Study: 12440557

Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Megesterol acetate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clonidine, methyldopa, and belladonna
Number of subjects: 0
Study: 9859550

Group type: EXPERIMENTAL
Intervention: Filmed modeling
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Coping skills
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Filmed modeling plus coping skills
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 7840069

Group type: EXPERIMENTAL
Intervention: alpha-LA-rich vegetable oil (flaxseed oil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dietary LA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary alpha-LA
Number of subjects: 0
Study: 2229775

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (no streptokinase)
Number of subjects: 73
Study: 840556

Group type: EXPERIMENTAL
Intervention: Daily phenobarbital
Number of subjects: 355

Group type: COMPARATOR
Intervention: Intermittent phenobarbital
Number of subjects: 355

Group type: COMPARATOR
Intervention: No phenobarbital
Number of subjects: 355
Study: 31343543

Group type: EXPERIMENTAL
Intervention: perindopril/indapamide/amlodipine (n = 101)
Number of subjects: 345

Group type: COMPARATOR
Intervention: perindopril/indapamide (n = 109)
Number of subjects: 345
Study: 27406787

Group type: EXPERIMENTAL
Intervention: Early diagnostic accuracy of clinical judgment of the ED physician for ACS in women
Number of subjects: 2795

Group type: COMPARATOR
Intervention: Early diagnostic accuracy of clinical judgment of the ED physician for ACS in men
Number of subjects: 2795

Group type: EXPERIMENTAL
Intervention: Late diagnostic uncertainty regarding the diagnosis of ACS in women
Number of subjects: 2795

Group type: COMPARATOR
Intervention: Late diagnostic uncertainty regarding the diagnosis of ACS in men
Number of subjects: 2795
Study: 26123286

Group type: EXPERIMENTAL
Intervention: Ferric(III)carboxymaltose infusion
Number of subjects: 198

Group type: COMPARATOR
Intervention: Ferrofumarate (oral iron supplementation)
Number of subjects: 198
Study: 23527241

Group type: EXPERIMENTAL
Intervention: CAD chest radiograph
Number of subjects: 1424

Group type: COMPARATOR
Intervention: Placebo control (imaged but not actually receiving a chest radiograph)
Number of subjects: 1424
Study: 21457153

Group type: EXPERIMENTAL
Intervention: Subcostal TAP catheters with 1 mg.kg(‐1) bupivacaine 0.375% every 8 h
Number of subjects: 62

Group type: COMPARATOR
Intervention: Epidural analgesia with bupivacaine 0.125% and fentanyl 2 μg.ml(‐1)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Subcostal TAP catheters
Number of subjects: 62
Study: 19318435

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome classification
Number of subjects: 2392

Group type: EXPERIMENTAL
Intervention: High waist circumference
Number of subjects: 2392

Group type: EXPERIMENTAL
Intervention: Elevated fasting glucose
Number of subjects: 2392

Group type: EXPERIMENTAL
Intervention: Combination of large waist circumference and elevated glucose
Number of subjects: 2392
Study: 16478779

Group type: EXPERIMENTAL
Intervention: Cirrhosis patients
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Post-liver transplantation patients
Number of subjects: 57
Study: 15023581

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid from patients with AD
Number of subjects: 19
Study: 11912568

Group type: EXPERIMENTAL
Intervention: Topiramate (512 mg/day)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Topiramate (not specified dosage)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 9470264

Group type: EXPERIMENTAL
Intervention: Minimal-intervention group (educational letter)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Maximal-intervention group (threat of enforcement)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Minimal-intervention group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Maximal-intervention group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Minimal-intervention group and Maximal-intervention group
Number of subjects: 300
Study: 8163132

Group type: EXPERIMENTAL
Intervention: Second-look endoscopy within the first 24 hours with repeated injection if a visible vessel was still identified
Number of subjects: 104
Study: 3286039

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP) 0.3 micrograms/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29331313

Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol
Number of subjects: 4528

Group type: COMPARATOR
Intervention: Formoterol alone
Number of subjects: 4528
Study: 27007999

Group type: EXPERIMENTAL
Intervention: Osteofortil®
Number of subjects: 24

Group type: COMPARATOR
Intervention: Forteo®
Number of subjects: 24
Study: 25899544

Group type: EXPERIMENTAL
Intervention: Multi-dimensional indoor and outdoor balance training (EXP)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Upper limb exercise (CON)
Number of subjects: 84
Study: 23750971

Group type: EXPERIMENTAL
Intervention: Same-room dyads
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Different-room dyads with audio
Number of subjects: 2

Group type: COMPARATOR
Intervention: Different-room dyads without audio
Number of subjects: 2
Study: 20458988

Group type: EXPERIMENTAL
Intervention: Frozen gel pack applied to sternal incision dressing before DB & C exercises
Number of subjects: 32

Group type: COMPARATOR
Intervention: No gel pack
Number of subjects: 32
Study: 18154801

Group type: EXPERIMENTAL
Intervention: Continuous ventilation during cardiopulmonary bypass
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonventilation during cardiopulmonary bypass
Number of subjects: 50
Study: 15577413

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) and Lamivudine (3TC)
Number of subjects: 16
Study: 11549104

Group type: COMPARATOR
Intervention: Theophylline (600 mg) alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tegaserod (6 mg) and Theophylline (600 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tegaserod (6 mg)
Number of subjects: 18
Study: 9928569

Group type: EXPERIMENTAL
Intervention: Infusional 5-FU 200 mg/m2 per day for up to 6 months in combination with 3-weekly bolus epirubicin (60 mg/m2) and cisplatin (60 mg/m2)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Infusional ECF
Number of subjects: 123
Study: 8150098

Group type: EXPERIMENTAL
Intervention: 12-week weight loss program (n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 12-week waiting list (control group, n = 6)
Number of subjects: 12
Study: 3229867

Group type: EXPERIMENTAL
Intervention: Propranolol therapy
Number of subjects: 50
Study: 31621349

Group type: EXPERIMENTAL
Intervention: ezParent Program implementation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Interest in participating in the ezParent Program
Number of subjects: 36
Study: 30431605

Group type: EXPERIMENTAL
Intervention: Modified quadruple therapy (proton‐pump inhibitor bid, amoxicillin 1 g bid, metronidazole 500 mg tid, bismuth subcitrate 300 mg qid daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bismuth‐containing quadruple therapy (proton‐pump inhibitor bid, tetracycline 500 mg qid, metronidazole 500 mg tid, bismuth subcitrate 300 mg qid daily)
Number of subjects: 0
Study: 26729448

Group type: EXPERIMENTAL
Intervention: Sirolimus-containing arm
Number of subjects: 139

Group type: COMPARATOR
Intervention: Standard regimens (tacrolimus, sirolimus and methotrexate)
Number of subjects: 139
Study: 25305762

Group type: EXPERIMENTAL
Intervention: 25‐µg sublingual misoprostol with vaginal placebo
Number of subjects: 131

Group type: COMPARATOR
Intervention: 50‐µg intravaginal misoprostol with sublingual placebo
Number of subjects: 131
Study: 22449658

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (n=74, 3 g intravenous injection before the procedure and oral 1 g per day for 2 days after the procedure)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Sodium chloride alone (n=82, control group)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 156

Group type: COMPARATOR
Intervention: Sodium chloride alone (control group)
Number of subjects: 156
Study: 20139126

Group type: EXPERIMENTAL
Intervention: Open-ended responses pooled with predefined responses
Number of subjects: 1664

Group type: COMPARATOR
Intervention: Predefined responses
Number of subjects: 1664
Study: 15667874

Group type: EXPERIMENTAL
Intervention: 2% rectal lidocaine gel
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 40% dimethyl sulfoxide (DMSO) with lidocaine
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Perianal injection of 1% lidocaine
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Periprostatic nerve block
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (lidocaine gel)
Number of subjects: 114
Study: 11336160

Group type: EXPERIMENTAL
Intervention: Fructose malabsorption (breath deltaH2 production >20 ppm)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal fructose absorption
Number of subjects: 50
Study: 9399445

Group type: EXPERIMENTAL
Intervention: Early surgery (<72 hours after spinal cord injury)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late surgery (>5 days after spinal cord injury)
Number of subjects: 0
Study: 8199601

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3297176

Group type: EXPERIMENTAL
Intervention: nortriptyline
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: phenelzine
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study: 31077858

Group type: EXPERIMENTAL
Intervention: Antibacterials in outpatient prescriptions at township health centers
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Antibacterials in outpatient prescriptions at community health service centers
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comparison between hospital A and hospital N in township health centers
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comparison between P center and T center
Number of subjects: 17
Study: 28374183

Group type: EXPERIMENTAL
Intervention: Ropivacaine (group R)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ropivacaine and dexmedetomidine (group RD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 0
Study: 25940520

Group type: EXPERIMENTAL
Intervention: DAPT interruption at any time
Number of subjects: 11219

Group type: EXPERIMENTAL
Intervention: Permanent DAPT discontinuation before 30 days
Number of subjects: 11219

Group type: EXPERIMENTAL
Intervention: Permanent DAPT discontinuation between 30 and 90 days
Number of subjects: 11219

Group type: EXPERIMENTAL
Intervention: DAPT discontinuation beyond 90 days
Number of subjects: 11219
Study: 23609776

Group type: EXPERIMENTAL
Intervention: Insoluble wheat bran fibre-containing breakfast cereal (5.4 g fibre, 3.5 g from wheat bran)
Number of subjects: 153
Study: 21606430

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus DTIC (10 mg/m2/min at 1800 mg/m2 followed by DTIC at 500 mg/m2 every 2 weeks)
Number of subjects: 113

Group type: COMPARATOR
Intervention: DTIC alone (1200 mg/m2 every 3 weeks)
Number of subjects: 113
Study: 19194189

Group type: EXPERIMENTAL
Intervention: Iron supplementation to lactating nonanemic mothers
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Low maternal iron reserves
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Low Hb level (<12 g/dL)
Number of subjects: 47
Study: 16126256

Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment with rtPA
Number of subjects: 108

Group type: COMPARATOR
Intervention: No thrombolytic treatment (Control)
Number of subjects: 108
Study: 15330958

Group type: EXPERIMENTAL
Intervention: 22‐G hollow needle (group I)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 22‐G caudal block needle (group II)
Number of subjects: 70
Study: 11233236

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy (40 Gy radiation, low-dose fraction cisplatin 7 mg/body/day for 5 days a week for 4 weeks, and 5-fluorouracil 350 mg/body/day for 28 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (high-dose fraction cisplatin 70 mg/m2/day on day 1 and 5-fluorouracil 700 mg/m2/day on days 1-5)
Number of subjects: 40